Mutations in the TP53 tumor suppressor gene occur in 50% of lung adenocarcinoma and associate with a poor prognosis, but…
en_news
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
We are delighted to announce that VHIO’s Rodrigo Dienstmann has been appointed as Editor-in-Chief of the European Society for Medical…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
The Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials, PRIME-ROSE project, which counts on VHIO’s participation, launched on July…
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
Co-authored by Pere Barba, a Lead Investigator of VHIO’s Experimental Hematology Group, results of a study published in Cancer Discovery…
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
In an invited viewpoint article published in the Cancer Discovery, co-authors Elena Garralda, Executive Director of VHIO’s Research Unit for…
